A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

If you are wondering whether Amgen’s recent share price puts it on sale or at a premium, and what that really means for your ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...